Application of Quality by Design to the characterization of the cell culture process of an Fc-Fusion protein

详细信息	查看全文 | 推荐本文 |

• 作者：Yolande Rouiller ; ¹ ; ^{yolande.rouiller@merckgroup.com} ; Thomas Solacroup¹ ; ^{thomas.solacroup@merckgroup.com} ; Vé ; ronique Deparis¹ ; ^{veronique.deparis@merckgroup.com} ; Marco Barbafieri¹ ; ^{marco.barbafieri@merckgroup.com} ; Ralf Gleixner¹ ; ^{ralf.gleixner@merckgroup.com} ; Hervé ; Broly¹ ; ^{herve.broly@merckgroup.com} ; Alex Eon-Duval¹ ; ^{alex.eon-duval@merckgroup.com}
• 关键词：Cell culture process ; Characterization ; Quality by Design (QbD) ; Design of Experiments (DoE) ; Design space ; Fc-Fusion protein
• 刊名：European Journal of Pharmaceutics and Biopharmaceutics
• 出版年：2012
• 期刊代码：16_09396411
• 类别：pha
• 出版时间：June, 2012
• 卷：81
• 期：2
• 页码：426-437
• 文件大小：916 K

摘要

The production bioreactor step of an Fc-Fusion protein manufacturing cell culture process was characterized following Quality by Design principles. Using scientific knowledge derived from the literature and process knowledge gathered during development studies and manufacturing to support clinical trials, potential critical and key process parameters with a possible impact on product quality and process performance, respectively, were determined during a risk assessment exercise. The identified process parameters were evaluated using a design of experiment approach. The regression models generated from the data allowed characterizing the impact of the identified process parameters on quality attributes. The main parameters having an impact on product titer were pH and dissolved oxygen, while those having the highest impact on process- and product-related impurities and variants were pH and culture duration. The models derived from characterization studies were used to define the cell culture process design space. The design space limits were set in such a way as to ensure that the drug substance material would consistently have the desired quality.